| Jun'18 | Jun'17 | Jun'16 | Jun'15 | Jun'14 | Jun'13 | Jun'12 | Jun'11 | Jun'10 |
|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||
173,768 | 150,852 | 137,879 | 51,909 | 42,078 | 69,580 | 85,135 | 71,901 | 53,880 |
Operating expenses | ||||||||
Cost of goods sold | ||||||||
59,374 | 35,395 | 23,166 | 44,392 | 45,965 | 30,078 | 24,261 | 28,916 | 28,322 |
Research and development | ||||||||
185,821 | 178,199 | 160,655 | 54,442 | 49,824 | 59,420 | 56,719 | 63,498 | 72,488 |
Selling, general and administrative | ||||||||
58,500 | 39,336 | 36,267 | 31,433 | 21,907 | 19,624 | 15,202 | 16,261 | 17,121 |
Total operating expenses | ||||||||
303,695 | 252,930 | 220,088 | 130,267 | 117,696 | 109,122 | 96,182 | 108,675 | 117,931 |
Gain on the Binimetinib and Encorafenib Agreements, net | ||||||||
- | - | - | 80,010 | 0 | 0 | - | - | - |
Gain on sale of CMC, net | ||||||||
- | - | - | 1,641 | 0 | 0 | - | - | - |
Loss from operations | ||||||||
-129,927 | -102,078 | -82,209 | 3,293 | -75,618 | -39,542 | -11,047 | -36,774 | -64,051 |
Other income (expense) | ||||||||
Interest income | ||||||||
4,470 | 796 | 243 | 68 | 77 | 55 | 32 | 406 | 864 |
Interest expense | ||||||||
10,814 | 12,333 | 10,874 | 10,247 | 9,716 | 11,258 | 11,624 | 15,507 | 15,749 |
Realized gain from marketable securities, net | ||||||||
- | - | - | - | 0 | 0 | - | - | - |
Realized gains on auction rate securities, net | ||||||||
- | - | - | - | - | - | - | 1,891 | 1,305 |
Loss on extinguishment and conversion of notes | ||||||||
-6,457 | 0 | 0 | - | - | -11,197 | -942 | -6,340 | - |
Change in fair value of notes payable | ||||||||
-2,387 | -2,600 | 0 | 0 | - | - | - | - | - |
Impairment loss related to cost method investment | ||||||||
0 | 1,500 | 0 | 0 | - | - | - | - | - |
Other, net | ||||||||
69 | 897 | 0 | 16,255 | - | - | - | - | - |
Total other income (expense), net | ||||||||
-15,119 | -14,740 | -10,631 | 6,076 | -9,639 | -22,400 | 12,534 | 19,550 | 13,580 |
Loss before income tax expense | ||||||||
-145,046 | -116,818 | -92,840 | - | - | - | - | - | - |
Income tax expense | ||||||||
2,300 | 0 | 0 | - | - | - | - | - | - |
Net loss | ||||||||
-147,346 | -116,818 | -92,840 | 9,369 | -85,257 | -61,942 | -23,581 | -56,324 | -77,631 |
Net loss | ||||||||
- | - | - | - | - | - | - | - | -77,631 |
Change in unrealized gain (loss) on marketable securities | ||||||||
-385 | -83 | 2 | 3 | 4 | -1 | -4 | -5,525 | 2,294 |
Comprehensive loss | ||||||||
-147,731 | -116,901 | -92,838 | 9,372 | -85,253 | -61,943 | -23,585 | -61,849 | -75,337 |
Weighted average shares outstanding – basic (in shares) | ||||||||
198,490 | 163,207 | 142,964 | 136,679 | 123,403 | 107,794 | - | - | - |
Weighted average shares outstanding – diluted (in shares) | ||||||||
198,490 | 163,207 | 142,964 | 141,692 | 123,403 | 107,794 | - | - | - |
Net loss per share – basic (in dollars per share) | ||||||||
-0.74 | -0.72 | -0.65 | 0.07 | -0.69 | -0.57 | - | - | - |
Net loss per share – diluted (in dollars per share) | ||||||||
-0.74 | -0.72 | -0.65 | 0.07 | -0.69 | -0.57 | - | - | - |
Weighted average shares outstanding basic and diluted | ||||||||
- | - | - | - | - | - | 70,619 | 55,447 | 50,216 |
Net loss per share basic and diluted | ||||||||
- | - | - | - | - | - | -0.33 | -1.02 | -1.55 |
Product royalties | ||||||||
Revenue | ||||||||
56,537 | 19,844 | 3,876 | 20,367 | 25,111 | 56,726 | 71,249 | 53,426 | 32,485 |
Collaboration and license revenue | ||||||||
Revenue | ||||||||
36,273 | 23,811 | 26,673 | 24,522 | 16,967 | 12,854 | 13,886 | 18,475 | 21,395 |
Reimbursement revenue | ||||||||
Revenue | ||||||||
80,958 | 107,197 | 107,330 | 7,020 | 0 | - | - | - | - |